<DOC>
	<DOCNO>NCT01203878</DOCNO>
	<brief_summary>The purpose study explore effect treat actinic keratoses face imiquimod 3.75 % cream follow photodynamic therapy comparison treatment imiquimod alone</brief_summary>
	<brief_title>Treatment Actinic Keratoses Face With Imiquimod 3.75 % Cream Followed Photodynamic Therapy</brief_title>
	<detailed_description>Actinic keratoses common skin lesion associate solar ultraviolet radiation exposure . Some actinic keratoses may develop skin cancer . Imiquimod 3.75 % cream approve treatment actinic keratoses utilizes regimen application entire face bald scalp 2 packet cream daily two 2-week cycle , separate 2-week treatment interval . Photodynamic therapy aminolevulinic acid ( ALA ) 20 % topical solution also approve treatment actinic keratoses . ALA apply actinic keratoses , incubation period , excite light . Although approved lesion-directed treatment actinic keratoses , treatment field ( e.g . face ) photodynamic therapy commonly perform . Treatment photodynamic therapy follow imiquimod 5 % cream report patient actinic keratoses , basal cell carcinoma Bowen 's disease , treatment imiquimod 5 % cream follow photodynamic therapy patient vulvar intraepithelial neoplasia . There , however , prior study safety and/or efficacy use topical imiquimod 3.75 % conjunction photodynamic therapy treatment actinic keratoses . This study use open-label parallel cohort design patient receive treatment imiquimod 3.75 % cream , subsequently randomize either photodynamic therapy observation .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Male female adult ; 18 At least 10 30 clinically typical actinic keratoses face Hypertrophic actinic keratoses skin lesion head might require exclude treatment study Known contraindication treatment imiquimod photodynamic therapy Condition would limit compliance , potential safety risk , require therapy exclude treatment Systemically immunocompromised Pregnant nursing Dermatologic disease and/or condition treatment area might exacerbate treatment imiquimod , cause difficulty examination , require therapy exclude treatment Participation another clinical study Treatment within past 60 day : Ultraviolet therapy Systemic immunomodulators Chemotherapeutic cytotoxic agent Investigational agent Treatment head within past 60 day : Imiquimod Photodynamic therapy Red blue light source therapy Cryotherapy chemotherapy Surgical excision curettage Topical corticosteroid Laser Dermabrasion Chemical peel Topical retinoids Topical 5fluorouracil Topical pimecrolimus tacrolimus Topical diclofenac Treatment actinic keratoses head within past 60 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Imiquimod</keyword>
	<keyword>Photodynamic therapy</keyword>
	<keyword>Actinic keratoses</keyword>
	<keyword>Sequential therapy</keyword>
	<keyword>Therapeutic us</keyword>
</DOC>